OrbiMed's 14% stake and two board seats provide significant influence, but the filing explicitly disclaims control intent and enumerates no specific proposals. Monitor for any future 13D amendments signaling a shift toward activist demands, particularly around strategic alternatives or operational changes, as the lock-up expiration (late March 2027) approaches.
Price Chart
Executive Summary
OrbiMed Advisors LLC and affiliated entities filed a Schedule 13D disclosing beneficial ownership of 14,913,764 shares of ADARx Pharmaceuticals, Inc., representing approximately 14.0% of the outstanding common stock. The stake was acquired through pre-IPO preferred stock conversions and IPO participation, and the filing states the investment was made without intent to control the company. Two OrbiMed designees (Carl L. Gordon and Erez Chimovits) serve on ADARx's board, giving OrbiMed board-level influence.
Key Financial Metrics
Key Facts
- OrbiMed Advisors LLC and affiliates collectively own 14,913,764 shares, or ~14.0% of ADARx common stock.
- Stake comprises 14,325,529 shares (13.4%) held by OrbiMed Private Investments VII, LP; 9,292,025 shares (8.7%) by OrbiMed Israel Partners II, LP; and 588,235 shares (0.6%) by OrbiMed Genesis Master Fund, LP.
- Shares were acquired through conversion of Series A, B, B-1, and C Preferred Stock upon IPO, plus IPO purchases at $17.00 per share.
- Carl L. Gordon and Erez Chimovits, both OrbiMed affiliates, serve on ADARx's Board of Directors.
- The filing states no plans for control, extraordinary transactions, board changes, or other enumerated actions.
- Lock-up agreements restrict sales by OPI VII, OIP II, Gordon, and Chimovits for 180 days after the IPO prospectus date (September 28, 2026).
- Registration rights (demand, piggyback, S-3) are held by the reporting persons under the Third Amended and Restated Investors' Rights Agreement.
Financial Impact
OrbiMed's aggregate stake value based on IPO price of $17.00/share is approximately $253.5 million (14,913,764 shares × $17.00).
Risk Factors
- OrbiMed could seek board changes or strategic review in future amendments despite current passive language.
- Lock-up expiration in ~6 months may lead to secondary sales, creating overhang.
- Registration rights could facilitate future share sales by OrbiMed, potentially pressuring the stock.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13D Filing (Primary) | 0000947871-26-000917 |
| Document: 0000947871-26-000917-index-headers.html | 0000947871-26-000917 |
| Document: 0000947871-26-000917-index.html | 0000947871-26-000917 |
| Document: 0000947871-26-000917.txt | 0000947871-26-000917 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | SC 13G | $17.63 $17.68 | ▲ +0.28% | ▼ −0.05% | $18.25 (+3.52%) |
Oct 5, 2026 21d ago | SC 13D | $18.58 $17.33 | ▼ −6.73% | ▼ −6.49% | $18.25 (−1.78%) |
Oct 2, 2026 24d ago | SC 13D | $19.05 $18.58 | ▼ −2.47% | ▼ −3.02% | $18.25 (−4.20%) |
Oct 1, 2026 25d ago | Press Release | $18.25 $19.05 | ▲ +4.38% | ▲ +3.71% | $18.25 (0.00%) |
Oct 1, 2026 25d ago | SC 13G | $18.25 $19.05 | ▲ +4.38% | ▲ +3.71% | $18.25 (0.00%) |
Sep 30, 2026 26d ago | Insider Cluster | $19.54 $18.25 | ▼ −6.60% | ▼ −7.34% | $18.25 (−6.60%) |
Sep 29, 2026 27d ago | Insider Cluster | $19.94 $19.54 | ▼ −2.01% | ▼ −2.18% | $18.25 (−8.48%) |
Sep 25, 2026 4w ago | 424B4 | $20.09 $20.64 | ▲ +2.71% | ▲ +2.90% | $18.25 (−9.16%) |
Sep 25, 2026 4w ago | EFFECT | $19.35 $20.09 | ▲ +3.82% | ▲ +4.57% | $18.25 (−5.68%) |
Sep 24, 2026 4w ago | Press Release | $19.35 $20.09 | ▲ +3.82% | ▲ +4.57% | $18.25 (−5.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers